BeOne Medicines (BEIGF) Gross Profit (2017 - 2026)

BeOne Medicines (BEIGF) has reported Gross Profit for 10 consecutive years, with $1.5 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Gross Profit rose 33.01% year-over-year to $1.5 billion in Q2 2026; TTM through Jun 2026 was $5.4 billion, a 39.65% increase from a year earlier, with the FY2025 full-year figure at $4.7 billion, up 45.34% from the prior year.
• Gross Profit was $1.5 billion for Q2 2026 at BeOne Medicines, up from $1.3 billion in the prior quarter.
• Over five years, Gross Profit peaked at $1.5 billion in Q2 2026 and troughed at $241.4 million in Q1 2022.
• A 5-year average of $776.4 million and a median of $738.0 million in 2023 frame the typical range for Gross Profit.
• The widest YoY moves for Gross Profit: up 137.76% in 2022, down 57.89% in 2022.
• Over 5 years, Gross Profit stood at $306.6 million in 2022, then surged by 72.41% to $528.6 million in 2023, then soared by 82.99% to $967.3 million in 2024, then jumped by 40.16% to $1.4 billion in 2025, then climbed by 12.89% to $1.5 billion in 2026.
• The last three Gross Profit figures came in at $1.5 billion (Q2 2026), $1.3 billion (Q1 2026), and $1.4 billion (Q4 2025), per Business Quant data.